# 04_QA_REPORT.md

> Quality Assurance Report — PP-0211 — CLDN18.2-targeted Therapy

## Identity

|Field|Value|
|---|---|
|QA Report ID|QA-PP-0211|
|PP ID|PP-0211|
|Title|CLDN18.2-targeted Therapy|
|Version|1.0.0|
|Status|Approved — GOLD|
|Decision State|Approved + Locked|
|Evidence Basis|Project Source Files — 18 core gastric-cancer materials plus approved governance/artifact references|

## QA Method

This QA report evaluates PP-0211 against the locked Population Package governance framework, the approved Decision Batch, the Gold artifact specification, the Source-First rule, adjacent-package boundary requirements, evidence traceability, patient-facing safety, and Knowledge Graph completeness.

The QA review does not replace clinical guideline review. It verifies that the package represents the supplied evidence faithfully, stays within the approved scope, avoids unsupported clinical expansion, and preserves the Gold production standard.

## Layer 1 — Content QA

|Criterion|Result|QA Note|
|---|---|---|
|Identity matches approved PP|PASS|PP-0211 is consistently identified as CLDN18.2-targeted Therapy.|
|Approved scope implemented|PASS|Core content follows the locked scope: biomarker-targeted therapy centered on zolbetuximab in the supported advanced setting.|
|One clinical educational question|PASS|The package explains what CLDN18.2-targeted therapy means and how it is used conceptually.|
|Included topics complete|PASS|Target, treatment context, zolbetuximab, pivotal evidence, safety, misconceptions, patient questions and boundaries are included.|
|Excluded topics respected|PASS|Detailed testing, scoring, dosing, chemotherapy management, immunotherapy and resistance are excluded/delegated.|
|No accidental FLOT ownership|PASS|FLOT remains delegated to PP-0204.|
|No accidental perioperative ownership|PASS|Perioperative/adjuvant/neoadjuvant treatment is not represented as a CLDN18.2-targeted core pathway.|
|No accidental testing ownership|PASS|Testing methodology and scoring remain upstream.|
|Internal consistency|PASS|Population, agent, evidence and safety statements remain consistent across CKO, KP and EP.|
|Patient-facing progression|PASS|Definition → biomarker relevance → treatment context → evidence → safety → misconceptions → questions.|

## Layer 1A — Completeness Review

- Definition and patient explanation included.
- Clinical importance included.
- Biomarker-treatment relationship included.
- Treatment context included.
- Zolbetuximab role included.
- Combination chemotherapy context included.
- SPOTLIGHT included.
- GLOW included.
- PFS and OS interpretation included.
- Safety and adverse-effect awareness included.
- Misconceptions included.
- Patient questions included.
- Knowledge Graph included.
- Boundary included.
- Evidence limitations included.
- Update triggers included.

## Layer 2 — Clinical QA

|Criterion|Result|QA Note|
|---|---|---|
|Source-grounded clinical claims|PASS|Claims are restricted to supplied Source Materials.|
|NCCN v2.2026 alignment|PASS|First-line zolbetuximab-containing pathway is represented for HER2-negative, CLDN18.2-positive, unresectable locally advanced/recurrent/metastatic disease.|
|NCI PDQ alignment|PASS|CAPOX and mFOLFOX6 are represented in the CLDN18.2-positive first-line treatment context.|
|NCI drug-list alignment|PASS|Zolbetuximab-clzb / Vyloy is identified as a stomach-cancer drug.|
|ACS alignment|PASS|Patient-facing CLDN18.2, zolbetuximab and adverse-effect descriptions are represented conservatively.|
|SPOTLIGHT figures|PASS|Median PFS 10.61 vs 8.67 months; HR 0.75. Median OS 18.23 vs 15.54 months; HR 0.75.|
|GLOW figures|PASS|Median PFS 8.21 vs 6.80 months; HR 0.687. Median OS 14.39 vs 12.16 months; HR 0.771.|
|Population definition|PASS|The package preserves HER2-negative and CLDN18.2-positive status and the advanced/unresectable/recurrent/metastatic context.|
|Combination therapy representation|PASS|The package does not imply zolbetuximab monotherapy in the pivotal paradigm.|
|Safety representation|PASS|Nausea/vomiting and other major adverse effects are acknowledged without creating a management algorithm.|
|No unsupported certainty|PASS|No guarantee of response or individualized survival claim is made.|
|No individualized prescribing|PASS|The package remains educational and directs individual decisions to the cancer care team.|
|No unsupported investigational expansion|PASS|Other CLDN18.2 agents are not presented as established treatment without Source support.|
|No guideline substitution|PASS|NCCN is primary; NCI/ACS/ESMO-ASCO are used for corroboration and educational context.|

## Layer 2A — Clinical Safety Review

|Safety Item|Result|Finding|
|---|---|---|
|No individualized treatment recommendation|PASS|No patient-specific prescription is made.|
|No individualized prognosis|PASS|Trial medians are explicitly described as population-level.|
|No false reassurance|PASS|Targeted therapy is not portrayed as low-risk or curative by default.|
|No biomarker determinism|PASS|CLDN18.2 positivity is not equated with guaranteed response.|
|No chemotherapy minimization|PASS|The combination nature of the evidence is explicit.|
|Adverse effects acknowledged|PASS|Gastrointestinal and other important toxicities are included.|
|Escalation to clinician|PASS|Patient questions direct individualized decisions and symptoms to the care team.|

## Layer 3 — Educational QA

|Criterion|Result|QA Note|
|---|---|---|
|Plain language|PASS|Technical terms are explained at first use or embedded in patient-oriented context.|
|Patient-friendly wording|PASS|Questions and explanations use direct, non-sensational language.|
|Logical flow|PASS|The package follows the clinical reasoning pathway from biomarker to treatment to evidence to safety.|
|Misconceptions addressed|PASS|Dedicated misconception section corrects common overinterpretations.|
|Uncertainty communicated|PASS|Evidence maturity and patient-specific uncertainty are explicit.|
|Practical usefulness|PASS|Patient questions provide a bridge to clinical discussion.|
|No overpromising|PASS|No guarantee of benefit, response or survival is stated.|
|Treatment burden visible|PASS|Safety information is not buried or minimized.|
|Terminology consistency|PASS|CLDN18.2, zolbetuximab, HER2-negative, SPOTLIGHT and GLOW are used consistently.|

## Layer 3A — Patient Misconception QA

|Potential Misconception|Result|Correction Present|
|---|---|---|
|Positive biomarker = automatic drug|PASS|Treatment context and individualized decision-making are explicit.|
|Targeted therapy = no chemotherapy|PASS|Pivotal combination regimens are explicitly described.|
|Positive biomarker = guaranteed response|PASS|Population-level evidence is distinguished from individual outcome.|
|All stages can receive the therapy|PASS|Advanced/unresectable/recurrent/metastatic setting is preserved.|
|HER2 status irrelevant|PASS|HER2-negative requirement is retained.|
|Targeted therapy = no toxicity|PASS|Nausea/vomiting and other adverse effects are explicitly covered.|

## Layer 4 — Governance QA

|Criterion|Result|QA Note|
|---|---|---|
|CKO completed|PASS|01_CKO.md produced.|
|Knowledge Passport completed|PASS|02_KNOWLEDGE_PASSPORT.md produced.|
|Evidence Package completed|PASS|03_PRIMARY_EVIDENCE_PACKAGE.md produced.|
|QA Report completed|PASS|04_QA_REPORT.md produced.|
|Gold specification followed|PASS|Four-artifact structure preserved.|
|Gold depth rule respected|PASS|Artifacts are full-depth and not compacted into summary-only outputs.|
|Source-First rule respected|PASS|Requested PP, governance, discussion template, registry and clinical Source Materials were searched before production.|
|Locked Decision Batch respected|PASS|No scope reopening after approval.|
|Adjacent overlap check|PASS|Testing, HER2-targeted therapy, general targeted therapy, FLOT, treatment-setting, drug-specific and toxicity ownerships are explicitly bounded.|
|Boundary structure|PASS|Core / Supporting / Explicitly Excluded / Delegated-to PP is declared.|
|Knowledge Graph|PASS|Prerequisite, related and downstream relationships are defined.|
|Versioning|PASS|Semantic version 1.0.0 used.|
|Artifact naming|PASS|Standard four filenames used.|
|ZIP packaging|PASS|All four artifacts packaged together.|
|Repository readiness|PASS|Package has a clean PP directory and four Markdown artifacts.|

## Adjacent Population Package Overlap Audit

|Adjacent Package / Node|Potential Collision|Resolution|Result|
|---|---|---|---|
|CLDN18.2 Testing|Biomarker positivity and eligibility|PP-0211 uses testing only as prerequisite; methodology remains upstream|PASS|
|CLDN18.2 IHC Testing|IHC details|Excluded from PP-0211|PASS|
|CLDN18.2 Scoring|Scoring threshold/adjudication|Excluded from PP-0211|PASS|
|Targeted Therapy in Gastric Cancer|Generic targeted-therapy principles|PP-0211 is specialized CLDN18.2 treatment node|PASS|
|HER2-targeted Therapy|Biomarker-targeted treatment|Parallel node; PP-0211 preserves HER2-negative context|PASS|
|Zolbetuximab|Same agent|PP-0211 owns modality-level context; drug-specific management delegated|PASS|
|SPOTLIGHT|Same trial|PP-0211 summarizes; dedicated trial node can own deep dive|PASS|
|GLOW|Same trial|PP-0211 summarizes; dedicated trial node can own deep dive|PASS|
|Chemotherapy|Combination backbone|PP-0211 describes only evidence-supported backbone context|PASS|
|FLOT|Gastric chemotherapy|FLOT delegated to PP-0204|PASS|
|Perioperative / Adjuvant / Neoadjuvant|Treatment setting|Not part of the supported PP-0211 core|PASS|
|Immunotherapy|Systemic modality|Separate branch|PASS|
|Toxicity / Supportive Care|Adverse-event management|PP-0211 awareness only; management delegated|PASS|
|CLDN18.2 Resistance|Resistance mechanisms|Conceptual mention only; detailed ownership delegated|PASS|

## Evidence Traceability QA

- Primary treatment claims trace to NCCN Gastric Cancer v2.2026.
- The CLDN18.2 treatment population traces to NCCN v2.2026.
- SPOTLIGHT and GLOW numerical outcomes trace to the NCCN v2.2026 discussion.
- Zolbetuximab drug identity is corroborated by the NCI drug list.
- CAPOX/mFOLFOX6 treatment context is corroborated by NCI PDQ.
- Patient-facing adverse-effect information is corroborated by ACS.
- General biomarker-directed treatment and targeted-therapy principles are contextualized by ESMO-ASCO 2023.

## Gold Depth Integrity Review

The package preserves the established four-artifact architecture.
The CKO contains identity, objectives, scope, independent clinical knowledge blocks, misconceptions, patient questions, Knowledge Graph, boundary and revision history.
The Knowledge Passport contains identity, classification, runtime metadata, clinical knowledge units, evidence maturity, boundary map, safety rules, Knowledge Graph, governance sources and revision history.
The Primary Evidence Package contains clinical question, intent, scope, primary/supporting sources, hierarchy, evidence findings, detailed appraisal, expanded evidence matrix, limitations, delegation, update triggers, Knowledge Graph, traceability and revision history.
The QA Report contains all four governance QA layers, safety review, misconception review, overlap audit, traceability review, Gold-depth review, package integrity review and final decision.
The package does not intentionally compact reasoning into a short summary or omit the Knowledge Graph, evidence traceability, patient-facing explanation or QA depth.

## Package Integrity Review

|Artifact|Present|Expected Role|
|---|---|---|
|01_CKO.md|YES|Clinical Knowledge Object|
|02_KNOWLEDGE_PASSPORT.md|YES|Runtime and governance passport|
|03_PRIMARY_EVIDENCE_PACKAGE.md|YES|Primary evidence traceability|
|04_QA_REPORT.md|YES|Four-layer QA and final status|

## Final Quality Decision

# PASS

PP-0211 satisfies the locked Gold Population Package structure and the approved/locked PP-0211 Decision Batch.

The package maintains the intended architecture:

**CLDN18.2 Testing**

↓

**Biomarker Testing for Targeted Therapy**

↓

**Targeted Therapy in Gastric Cancer**

↓

# PP-0211 — CLDN18.2-targeted Therapy

↓

**Zolbetuximab / SPOTLIGHT / GLOW / downstream drug-specific management**

The package does not duplicate substantive ownership of CLDN18.2 testing methodology, scoring, general targeted therapy, HER2-targeted therapy, FLOT, perioperative treatment, immunotherapy, detailed drug management, or detailed toxicity/resistance packages.

## Reviewer Notes

PP-0211 functions as the specialized treatment node that translates a clinically relevant CLDN18.2 result into an evidence-grounded treatment concept without turning biomarker positivity into an automatic prescription.

The principal safety safeguards are:

1. **CLDN18.2-positive → not automatically treatment-required.**
2. **Biomarker-positive → not guaranteed response.**
3. **Targeted therapy → not chemotherapy-free in the established zolbetuximab paradigm.**
4. **Trial median → not individualized prognosis.**
5. **Advanced-setting evidence → not automatically extrapolated to early/resectable disease.**

## Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
## Detailed Content Audit

### Identity audit

- PP number: PP-0211 — PASS.
- Title: CLDN18.2-targeted Therapy — PASS.
- Treatment domain: biomarker-directed targeted therapy — PASS.
- Version: 1.0.0 — PASS.
- Locked status: represented as Approved — GOLD — PASS.

### Scope audit

The approved scope is represented across all four artifacts.

The following core concepts appear consistently:

- CLDN18.2 target;
- biomarker-treatment relationship;
- HER2-negative context;
- advanced/unresectable/recurrent/metastatic disease;
- zolbetuximab;
- chemotherapy combination;
- SPOTLIGHT;
- GLOW;
- efficacy;
- safety;
- patient-facing interpretation;
- boundary/delegation.

### Exclusion audit

The following are explicitly excluded:

- detailed IHC;
- detailed scoring;
- detailed laboratory methods;
- detailed zolbetuximab dosing;
- detailed chemotherapy management;
- FLOT;
- perioperative therapy;
- neoadjuvant therapy;
- adjuvant therapy;
- detailed immunotherapy;
- detailed resistance;
- individualized treatment;
- individualized prognosis.

## Detailed Clinical Claim Audit

| Claim | Source support present | Overclaim check | Result |
|---|---|---|---|
| CLDN18.2 is a target | NCCN/ACS | Not generalized beyond gastric/EGJ treatment context | PASS |
| CLDN18.2 testing matters | NCCN | Testing method delegated | PASS |
| HER2-negative is part of pathway | NCCN | Preserved | PASS |
| Advanced/unresectable setting | NCCN/NCI | Not extrapolated to early disease | PASS |
| Zolbetuximab targets CLDN18.2 | NCCN/ACS | Correct | PASS |
| Combination with chemotherapy | NCCN/NCI | No monotherapy claim | PASS |
| SPOTLIGHT benefit | NCCN | Numbers preserved | PASS |
| GLOW benefit | NCCN | Numbers preserved | PASS |
| Nausea/vomiting | NCCN/ACS | No management algorithm | PASS |
| Other adverse effects | ACS/NCCN | Framed as awareness | PASS |
| Individual response | Not directly claimable | Explicitly qualified | PASS |
| Individual prognosis | Not directly claimable | Explicitly excluded | PASS |

## Detailed Boundary Audit

### Boundary 1 — CLDN18.2 Testing

**Risk:** PP-0211 could accidentally reproduce IHC methodology.

**Control:** The CKO and Evidence Package explicitly state that testing/scoring are delegated.

**Result:** PASS.

### Boundary 2 — Targeted Therapy in Gastric Cancer

**Risk:** PP-0211 could become a second generic targeted-therapy package.

**Control:** General targeted-therapy principles are limited to a bridge; the substantive content is CLDN18.2-specific.

**Result:** PASS.

### Boundary 3 — HER2-targeted Therapy

**Risk:** HER2 and CLDN18.2 treatment could be merged.

**Control:** HER2-negative status is retained as a treatment-context qualifier; HER2-targeted treatment remains a parallel node.

**Result:** PASS.

### Boundary 4 — Zolbetuximab

**Risk:** PP-0211 could become a drug monograph.

**Control:** Drug-specific dosing, administration and detailed toxicity management are delegated.

**Result:** PASS.

### Boundary 5 — FLOT

**Risk:** Gastric chemotherapy content could drift into FLOT.

**Control:** FLOT is explicitly excluded and delegated to PP-0204.

**Result:** PASS.

### Boundary 6 — Perioperative / Neoadjuvant / Adjuvant

**Risk:** A targeted therapy package could be generalized to all treatment stages.

**Control:** PP-0211 retains the advanced/unresectable/recurrent/metastatic evidence setting and excludes these settings.

**Result:** PASS.

### Boundary 7 — Immunotherapy

**Risk:** CLDN18.2 could be mixed with PD-L1/MSI treatment.

**Control:** Immunotherapy is a separate treatment branch.

**Result:** PASS.

### Boundary 8 — Resistance

**Risk:** Progression discussion could expand into a resistance package.

**Control:** Only conceptual progression/reassessment is included; detailed resistance is delegated.

**Result:** PASS.

## Detailed Patient-Safety Audit

### Safety principle 1

The package never states:

> “This treatment is safe.”

Instead it communicates:

> treatment has meaningful adverse effects and requires monitoring.

**PASS.**

### Safety principle 2

The package never states:

> “CLDN18.2-positive means treatment will work.”

Instead it distinguishes biomarker selection from response.

**PASS.**

### Safety principle 3

The package never instructs a patient to start, stop, or change treatment.

**PASS.**

### Safety principle 4

The package never provides individualized dosing.

**PASS.**

### Safety principle 5

The package never provides individualized survival estimates.

**PASS.**

### Safety principle 6

The package provides patient-facing questions that support discussion with the oncology team.

**PASS.**

## Detailed Educational Audit

### Definition

Present and understandable.

**PASS.**

### Clinical significance

Present and linked to treatment.

**PASS.**

### Treatment pathway

Present and appropriately bounded.

**PASS.**

### Evidence

Pivotal randomized evidence is explained.

**PASS.**

### Uncertainty

Explicitly addressed.

**PASS.**

### Safety

Visible and not minimized.

**PASS.**

### Misconceptions

Dedicated section included.

**PASS.**

### Practical utility

Patient questions included.

**PASS.**

### Terminology

Medical terms are introduced with explanatory context.

**PASS.**

## Knowledge Graph Audit

### Upstream links

- CLDN18.2 Testing.
- Biomarker Testing for Targeted Therapy.
- Targeted Therapy in Gastric Cancer.

**PASS.**

### Parallel links

- HER2-targeted Therapy.
- Chemotherapy.
- Immunotherapy.

**PASS.**

### Downstream links

- Zolbetuximab.
- SPOTLIGHT.
- GLOW.
- Toxicity/supportive care.
- Resistance.

**PASS.**

### Boundary semantics

The graph does not assign the same substantive content to multiple nodes.

**PASS.**

## Evidence Traceability Audit

The following high-impact claims were explicitly traceable:

1. CLDN18.2 biology/target rationale → NCCN.
2. Testing context → NCCN.
3. HER2-negative pathway → NCCN.
4. Zolbetuximab identity → NCCN/NCI/ACS.
5. First-line combination → NCCN/NCI PDQ.
6. SPOTLIGHT → NCCN.
7. GLOW → NCCN.
8. Safety → NCCN/ACS.
9. Patient-facing treatment context → NCI/ACS.
10. General targeted-therapy framework → ESMO-ASCO.

**Result: PASS.**

## Numerical Evidence Audit

### SPOTLIGHT

- N = 565 — PASS.
- PFS 10.61 vs 8.67 months — PASS.
- PFS HR 0.75 — PASS.
- OS 18.23 vs 15.54 months — PASS.
- OS HR 0.75 — PASS.

### GLOW

- N = 507 — PASS.
- PFS 8.21 vs 6.80 months — PASS.
- PFS HR 0.687 — PASS.
- OS 14.39 vs 12.16 months — PASS.
- OS HR 0.771 — PASS.

No numerical claim was used to make an individualized prognosis.

**Result: PASS.**

## Version-Control Audit

| Item | Result |
|---|---|
| Semantic versioning | PASS |
| Initial release = 1.0.0 | PASS |
| No unnecessary major version | PASS |
| No hidden scope change | PASS |
| Approved Decision Batch preserved | PASS |

## Gold Artifact Structure Audit

### 01_CKO.md

Required elements verified:

- Metadata;
- educational objectives;
- included scope;
- excluded scope;
- independent clinical knowledge blocks;
- patient explanation;
- clinical importance;
- misconceptions;
- key messages;
- patient questions;
- Knowledge Graph;
- boundary;
- revision history.

**PASS.**

### 02_KNOWLEDGE_PASSPORT.md

Required elements verified:

- identity;
- classification;
- runtime metadata;
- retrieval logic;
- knowledge units;
- evidence maturity;
- boundary map;
- safety rules;
- Knowledge Graph;
- governance sources;
- maintenance rules;
- revision history.

**PASS.**

### 03_PRIMARY_EVIDENCE_PACKAGE.md

Required elements verified:

- identity;
- clinical question;
- educational intent;
- scope;
- primary sources;
- supporting sources;
- evidence hierarchy;
- findings;
- detailed evidence appraisal;
- evidence matrix;
- evidence limitations;
- delegation;
- update triggers;
- Knowledge Graph;
- traceability;
- revision history.

**PASS.**

### 04_QA_REPORT.md

Required elements verified:

- identity;
- QA method;
- content QA;
- clinical QA;
- educational QA;
- governance QA;
- clinical safety;
- misconception review;
- overlap audit;
- traceability;
- Gold depth review;
- package integrity;
- final decision.

**PASS.**

## Gold Depth Integrity — Final Audit

The package was checked specifically against the project’s absolute Gold-depth requirement.

### The following were NOT compacted:

- clinical reasoning;
- evidence discussion;
- trial interpretation;
- patient-facing explanation;
- Knowledge Graph;
- boundary analysis;
- evidence traceability;
- safety review;
- governance QA;
- overlap audit;
- update triggers.

### The package does not rely on:

- a short executive summary as a substitute for the CKO;
- a minimal metadata table as a substitute for the Knowledge Passport;
- a short bibliography as a substitute for the Evidence Package;
- a checklist-only QA report.

**Gold-depth integrity: PASS.**

## Source-First Audit

Before production, the Source Files were searched for:

- PP-0211 identity;
- PP Registry;
- approved Decision Batch context;
- Gold Discussion example;
- Gold artifact examples;
- governance;
- NCCN v2.2026;
- NCI PDQ;
- NCI treatment;
- NCI drug list;
- ACS;
- ESMO-ASCO.

Relevant source evidence was located and incorporated.

**PASS.**

## Locked Decision Integrity

The production did not reopen:

- scope;
- depth;
- format;
- artifact structure;
- ZIP packaging;
- boundary architecture.

The approved recommendation was implemented directly.

**PASS.**

## QA Exceptions

No critical QA exception identified.

No architectural blocker identified.

No unresolved evidence conflict affecting the approved core scope identified.

## Reviewer Conclusion

PP-0211 is an atomic treatment Population Package.

Its architectural role is:

**CLDN18.2 Testing**

↓

**Biomarker-Directed Treatment Selection**

↓

**Targeted Therapy in Gastric Cancer**

↓

**PP-0211 — CLDN18.2-targeted Therapy**

↓

**Zolbetuximab**

↓

**Drug-specific / trial-specific / toxicity / resistance downstream nodes**

This placement prevents duplicate ownership while preserving a clinically meaningful patient-facing treatment explanation.

## Final Quality Decision

# PASS — GOLD

The four-artifact package is complete, source-grounded, boundary-controlled, clinically cautious, and ready for integration.

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**

## Additional Governance Verification

### Execution Sequence

The package was produced only for the explicitly requested PP-0211.

No inference of a subsequent PP was used.

**PASS.**

### Source-First Verification

The following Source File classes were checked before production:

- CORE_WORKING_RULES;
- FREEZE GOLD POPULATION PACKAGE SPECIFICATION;
- PP Discussion depth and format example;
- PP Registry;
- Gold artifact references;
- NCCN Gastric Cancer v2.2026;
- NCI Gastric Cancer Treatment PDQ;
- NCI Treatment of Stomach Cancer;
- NCI Drugs Approved for Stomach Cancer;
- ACS Stomach Cancer;
- ACS Chemotherapy for Stomach Cancer;
- ACS Immunotherapy for Stomach Cancer;
- ESMO-ASCO 2023.

**PASS.**

### Decision Lock Handling

The Project Coordinator explicitly approved and locked the PP-0211 Decision Batch.

No scope decision was reopened.

No additional format/depth confirmation was requested.

**PASS.**

## Extended Clinical Safety Audit

### Risk A — Biomarker overinterpretation

**Potential harm:** A patient may interpret a positive result as a guaranteed treatment or response.

**Control:** The package repeatedly states that biomarker positivity is one treatment-selection input and does not guarantee benefit.

**PASS.**

### Risk B — Stage overextension

**Potential harm:** A patient with early/resectable disease could assume the same evidence applies.

**Control:** The advanced/unresectable/recurrent/metastatic setting is explicitly maintained.

**PASS.**

### Risk C — Treatment-line overextension

**Potential harm:** First-line trial evidence could be interpreted as a later-line recommendation.

**Control:** Treatment-naive/first-line context is repeatedly identified.

**PASS.**

### Risk D — Combination misunderstanding

**Potential harm:** A patient could believe zolbetuximab replaces chemotherapy.

**Control:** Both pivotal regimens are described as combination therapy.

**PASS.**

### Risk E — Toxicity minimization

**Potential harm:** “Targeted” could be interpreted as “harmless.”

**Control:** Gastrointestinal, hematologic, hepatic and electrolyte adverse effects are explicitly discussed.

**PASS.**

### Risk F — Prognostic misuse

**Potential harm:** Trial median OS could be mistaken for an individual prognosis.

**Control:** The package explicitly distinguishes population-level evidence from individual prediction.

**PASS.**

### Risk G — Dosing misuse

**Potential harm:** A patient could act on incomplete dosing information.

**Control:** Detailed dosing is excluded and delegated.

**PASS.**

### Risk H — Laboratory misuse

**Potential harm:** A patient could use the treatment package to interpret a CLDN18.2 score.

**Control:** Detailed IHC/scoring is delegated to testing packages.

**PASS.**

## Clinical Wording Audit

The following wording principles were applied:

- “can be considered” rather than “must receive” when describing treatment relevance;
- “in the studied population” when describing trial benefit;
- “may occur” rather than absolute toxicity statements;
- “population-level” rather than individualized prognosis;
- “treatment context” rather than “automatic eligibility”;
- “high-level mechanism” rather than detailed pharmacology.

**PASS.**

## Unsupported-Claim Audit

### No claim that:

- all CLDN18.2-positive tumors benefit;
- all stages should receive zolbetuximab;
- FLOT is an evidence-supported zolbetuximab backbone;
- zolbetuximab monotherapy is the pivotal paradigm;
- every later-line patient should receive zolbetuximab;
- every investigational CLDN18.2 drug is clinically established;
- a CLDN18.2 result alone determines treatment;
- a CLDN18.2 result alone determines prognosis.

**PASS.**

## Source Hierarchy Audit

### Primary

NCCN v2.2026.

**PASS.**

### Independent corroboration

NCI PDQ.

**PASS.**

### Patient-facing corroboration

NCI treatment page and ACS.

**PASS.**

### Cross-cutting professional framework

ESMO-ASCO.

**PASS.**

The package does not treat a patient-facing source as higher authority than the disease-specific guideline for regimen claims.

**PASS.**

## Evidence Number Audit

The following numbers were independently rechecked against the retrieved NCCN source:

### SPOTLIGHT

- 565 patients.
- 10.61 vs 8.67 months median PFS.
- HR 0.75.
- 18.23 vs 15.54 months median OS.
- HR 0.75.

### GLOW

- 507 patients.
- 8.21 vs 6.80 months median PFS.
- HR 0.687.
- 14.39 vs 12.16 months median OS.
- HR 0.771.

No discrepancy identified.

**PASS.**

## Adverse-Event Audit

NCCN:

- nausea;
- vomiting;
- anemia;
- neutropenia;
- decreased appetite.

ACS:

- nausea;
- vomiting;
- diarrhea;
- fatigue;
- decreased appetite;
- abdominal pain;
- weight loss;
- constipation;
- sensory neuropathy;
- low blood counts;
- abnormal liver tests;
- electrolyte changes.

The final package presents these as awareness-level information.

It does not infer frequencies beyond the supplied evidence.

**PASS.**

## Knowledge Graph Integrity Audit

### Upstream

CLDN18.2 Testing.

**PASS.**

### Parent context

Biomarker Testing for Targeted Therapy.

**PASS.**

### General modality context

Targeted Therapy in Gastric Cancer.

**PASS.**

### Current node

PP-0211 CLDN18.2-targeted Therapy.

**PASS.**

### Downstream

Zolbetuximab.

SPOTLIGHT.

GLOW.

Toxicity/supportive care.

Resistance.

**PASS.**

### Parallel branches

HER2-targeted Therapy.

Immunotherapy.

Chemotherapy.

**PASS.**

## Repository Integrity Audit

Expected directory:

```text
PP-0211_CLDN18.2-targeted_Therapy_GOLD_v1.0/
├── 01_CKO.md
├── 02_KNOWLEDGE_PASSPORT.md
├── 03_PRIMARY_EVIDENCE_PACKAGE.md
└── 04_QA_REPORT.md
```

All four artifacts are present.

**PASS.**

## ZIP Integrity Audit

The ZIP package contains exactly the four required Markdown artifacts under the PP-0211 package directory.

No unrelated clinical files were inserted.

**PASS.**

## Final Cross-Artifact Consistency

### Title

All four artifacts use:

**PP-0211 — CLDN18.2-targeted Therapy**

**PASS.**

### Version

All four artifacts use:

**1.0.0**

**PASS.**

### Scope

All four artifacts preserve the same atomic scope.

**PASS.**

### Evidence

The same primary source hierarchy is preserved.

**PASS.**

### Boundary

The same ownership logic is preserved.

**PASS.**

### Knowledge Graph

The same upstream/parallel/downstream structure is preserved.

**PASS.**

### Safety

The same non-individualized treatment boundary is preserved.

**PASS.**

## Final Reviewer Checklist

| Review Item | Status |
|---|---|
| Correct PP identity | PASS |
| Correct title | PASS |
| Approved Decision Batch implemented | PASS |
| Source-first completed | PASS |
| 18 core clinical PDFs treated as evidence base | PASS |
| NCCN v2.2026 prioritized | PASS |
| NCI corroboration included | PASS |
| ACS patient-facing evidence included | PASS |
| ESMO-ASCO framework included appropriately | PASS |
| CLDN18.2 testing boundary preserved | PASS |
| HER2 boundary preserved | PASS |
| Generic targeted-therapy boundary preserved | PASS |
| Zolbetuximab boundary preserved | PASS |
| FLOT boundary preserved | PASS |
| Perioperative/neoadjuvant/adjuvant boundary preserved | PASS |
| Immunotherapy boundary preserved | PASS |
| Resistance boundary preserved | PASS |
| Individualized prescribing excluded | PASS |
| Individualized prognosis excluded | PASS |
| Four artifacts complete | PASS |
| ZIP complete | PASS |
| Gold depth maintained | PASS |
| Knowledge Graph complete | PASS |
| Evidence traceability complete | PASS |
| QA complete | PASS |

## Final Production Statement

PP-0211 is a complete governed Population Package.

The package is:

- atomic;
- patient-centered;
- source-grounded;
- evidence-traceable;
- boundary-controlled;
- Knowledge-Graph connected;
- clinically cautious;
- Gold-structured;
- repository-ready.

## Final Status

# PASS

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
